First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
The pilot plant is focused on scaling up beverage production and will support applications
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Pharma Solutions operates 10 research and development and/or production sites globally
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Subscribe To Our Newsletter & Stay Updated
